Added to YB: 2026-08-14
Pitch date: 2026-08-12
LQDA [neutral]
Liquidia Corporation
-9.5%
current return
Author Info
Value with a Catalyst covers long value oriented small and mid- cap investment ideas with a catalyst. Sign up for the newsletter.
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Market Cap
$7.1B
Pitch Price
$79.67
Price Target
184.00 (+155%)
Dividend
N/A
EV/EBITDA
40.62
P/E
53.31
EV/Sales
15.42
Sector
Pharmaceuticals
Category
growth
Liquidia - Q2 2026 Update
LQDA (earnings): Q2 added 5pts share to 30%; 50% share (~$1.4B sales, $776M NI, $862M cash) possible by Q2 2027. 20x run-rate NI = $184 PT, haircut 20% for legal risk to $147 vs $84 today. Risks: Judge Andrew's patent ruling (expect win), Insmed next-gen TPIP once-daily threat vs LQDA's L606.
Read full article (2 min)